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complemented by a boost to local recurrence to a total dose 
of 72 Gy. In case of no macroscopic tumor recurrence the 
total dose was 66.6 Gy. 
 
Results: MRI was performed in 233 patients and PET/CT was 
performed in 169 patients. A local recurrence in the prostate 
bed could be detected in 123 patients with a median volume 
of 0.5 ml (range, 0.03 – 125.00 ml). The median follow-up 
time after RT was 49.4 months (range, 7.3 – 86.1 months). A 
total of 85 patients experienced a biochemical failure with a 
median time of 19.8 months (range, 1.9 – 76.1 months) after 
sRT. Median PSA level at the time of recurrence was 0.91 
ng/ml (range, 0.01 – 2224.00 ng/ml). The median BRFS after 
radiation therapy was 73 months. The estimated 3- and 5-
year bRFS was 72% and 55%, respectively. On multivariate 
analysis, Gleason Score (hazard ratio, 6.946; p = 0.006) and 
pre-RT PSA level (hazard ratio, 2.265; p = 0.022) were 
statistically significant predictors for bRFS. bRFS was similar 
in patients with a macroscopic recurrence in either MRI or 
PET/CT compared to patients without a macroscopic 
recurrence. 5-year overall survival was 91% and 5-year 
cancer-specific survival was 96%. Grade 3 gastrointestinal 
toxicity was observed in 4 patients and 3 patients showed 
grade 3 genitourinary toxicities. No grade 4 gastrointestinal 
or genitourinary side effects were reported. 
 
Conclusion: Gleason score and pre-RT PSA were important 
predictors for bRFS. The dose in salvage radiotherapy should 
be increased to 72 Gy to prevent an early recurrence after 
sRT in patients with a macroscopic recurrence. A higher total 
dose of up to 72 Gy was well tolerated in this cohort of 
patients. 
 
EP-1383  
PSA kinetics in prostate cancer patients after SBRT 
radiotherapy using CyberKnife. 
M. Konkol
1Greater Poland Cancer Centre, Oddzial Radioterapii I I 
Radiotherapy Dept., Poznan, Poland 
1, A. Galuba1, P. Milecki1, A. Skrobala2, A. Jodda2, 
M. Adamczyk2, J. Litoborska2 
2Greater Poland Cancer Centre, Department of Medical 
Physics, Poznan, Poland 
 
Purpose or Objective: The aim of the study was to assess the 
kinetics of the Prostate-Specific Antigen (PSA) in prostate 
cancer patients after stereotactic body radiotherapy using 
CyberKnife System.  
 
Material and Methods: 44 localized prostate adenocarcinoma 
patients (33 low and 11 intermediate risk) without hormonal 
therapy, were irradiated using the CyberKnife Radiosurgical 
System. The prescription dose was 36,25 Gy in five fractions. 
During the 1-year follow-up all the patients had at least six 
PSA measurements – before the treatment (1-2 months before 
RT), during RT (after the 4th fraction) and 1, 3, 6, 12 months 
after RT.  
 
Results: The mean initial PSA value among the patients was 
6,25 ng/ml (range from 3,02 to 17,46 ng/ml). During the 
treatment we observe the PSA increase – the mean value was 
11,89 ng/ml (4,13-30,68ng/ml, 155% of the initial PSA in 
average). In every case we noticed the PSA nadir 12 months 
after the treatment with a mean value of 1,50 ng/ml (0,10- 
4,56 ng/ml). The mean slope of the PSA was 0,56 
ng/ml/month (median 0,46 ng/ml/month). No biochemical 
failure was observed. 
 
Conclusion: The PSA kinetics after treatment can reflect the 
biological effect of radiation on prostate cancer and 
potentially correlate with a clinical outcome. Especially the 
lower value of PSA nadir (<0,5 ng/ml) is considered to 
associate with an increased freedom from biochemical 
failure. The interpretation of PSA slope is more controversial 
however some studies indicates a correlation with clinical 
outcome. Our results are similar to other SBRT studies and 
significantly better than in conventionally-fractionated 
technics. The rapid decline in PSA is particularly worth to be 
underlined. The further follow-up will probably confirm the 
expected good clinical outcome. 
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Purpose or Objective: To describe and compare acute 
toxicity rate in three different radiotherapy (RT) protocols 
for prostate cancer (PC): hypofractionated radiotherapy 
intensity modulated and image-guided radiation therapy 
(Hypo-IMRT-IGRT) group A: 21 fractions/3Gy and group B: 28 
fractions/2.5Gy) and three-dimensional conformal 
radiotherapy standard fractionation (3DCRT) group C: 39 
fractions/2Gy. 
 
Material and Methods: Patients with the diagnosis of PC 
treated with RT between January 1st 2011 to June 30th 2015 
were included. Hypo-IMRT-IGRT were performed using 
internal marker and ExacTrac-X-Ray-system. In 3DCRT group 
not employed internal marker. Acute genitourinary (AGUT) 
and acute gastrointestinal toxicity (AGIT) were assessed 
according to RTOG-EORTC criteria. A p value<0.05 was 
considered significant. Results were expressed as median 
(IQR). Categorical and continuous variables were compared 
with X2 and kruskal-Wallis ran sum test respectively. All 
statistical analysis was performed using R package. The 
institutional review board approved this study. 
 
Results: 242 consecutive patients were retrospectively 
analyzed (group A: 39, group B: 128 and group C: 74). No 
baseline characteristic differences were found (age, PSA, 
TNM, PTV total, bladder and rectal volume). Maximal bladder 
doses and V60 rectal were different within the three groups 
(p=<0.01). AGUT (n): in group A was grade 0: 18; grade 1: 9, 
grade 2: 12; group B grade 0: 35; grade 1: 86; grade 2: 7; and 
group C grade 0: 23; grade 1: 38; grade 2: 13 (p=<0.01). AGIT 
was in group A grade 0: 38; grade 1: 1; grade 2: 0; group B 
grade 0: 121; grade 1: 7; grade 2: 0; and group C grade 0: 65; 
grade 1: 6; grade 2: 3 (p=0.07) Table 1. Comparative AGUT 
between A+B vs. C did not differ. AGIT in A+B group was less 
frequent than C group (p=0.017). AGUT from group A was 
different from group B (p=<0.01). AGIT from A group was not 
different from B group (p=0.75).There were no events > 
grade 3 reported in any group. 
GRADE n( %) 0 1 2 p 
AGUT     <0.01 
Group A  18(46) 9(23) 12(31)  
Group B 35(27) 86(67) 7(5)  
Group C 23(31) 38(51) 38(51)  
AGIT    0.07 
Group A 38(97) 1(3) 0(0)  
Group B 121(95) 7(5) 0(0)  
Group C  65(88) 6(8) 3(4)  
 
Conclusion: Hypo-IMRT-IGRT was associated to lower AGIT 
rate than 3DCRT. Hypo-IMRT-IGRT 21 fractions/3Gy was 
inferior to Hypo-IMRT-IGRT 28 fractions in terms of AGUT. 
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Purpose or Objective: For the locally advanced prostate 
cancers (LAPC) dose escalated external beam Radiotherapy 
(dEBRT) with androgen deprivation therapy (ADT) for 2-3 
years is the current standard of care. The role of radical 
prostatectomy (RP) for high-risk prostate cancer is still 
debated. Better outcomes with RP as compared to dEBRT 
especially <69 years of age has been reported. However there 
is no data available from India to compare dEBRT and RP. We 
did a retrospective study to compare dEBRT or RP in patients 
with LAPC.  
 
Material and Methods: Medical records of 77 high risk LAPC 
treated between 2008-2013 were analysed. All biopsy proven 
adenocarcinoma of prostate with high risk category 
(PSA>20ng/ml or Gleason score (GS) >7 or T2c-T4) were 
included. Patients either underwent dEBRT with image 
guided RT (IGRT) (group 1) or RP (group 2) along with ADT for 
2-3 years. Group 1 and 2 had 37 and 40 patients respectively. 
The primary end points of the study were biochemical relapse 
free survival (bRFS), bladder and rectal toxicity, urinary 
incontinence (UI) and secondary end point was cancer 
specific survival (CSS). 
 
Results: Median age and median pre-treatment PSA in 2 
groups were comparable (66 and 65years) and (22 and 23 
ng/ml) respectively. Radiologically T3/T4 lesions were 
present in 65% and 68% and nodal metastasis was seen in 22% 
and 30% respectively. Median GS was 8 and 7. Positive 
surgical margins was seen in 70% in group 2. dEBRT dose was 
76Gy with conventional fractionation using IGRT using 
fiducial marker matching . With a median follow up of 3 
years, 5-year bRFS was 78% and 72%. (p=0.12) .Median bRFS 
was not reached in group 1 and in group 2, it was 79 months. 
Post treatment UI was seen in 0 and 6(15%)(p=0.03). 
Radiation Therapy Oncology Group (RTOG) grade III-IV 
bladder toxicity (hematuria and bladder neck contracture 
requiring incision) was seen in 2(6%) and 7(18%) respectively 
and rectal toxicity in 2(6%) and peroperative rectal injury 
occurred in 2(5%) in group 2. Five year CSS was 65% and 87% 
respectively (p=0.086). Median CSS was not reached in any 
group. Six (16%) and 7(18%) patients were lost to follow up. 
Distant metastasis was seen in 8(22%) and 1(3%) (p=0.14). 
 
Conclusion: UI is the complication associated with RP. Dose 
escalated IGRT for LAPC is no different from RP in terms of 
bRFS however there was a trend towards better CSS and 
distant DFS. Further long term follow up is needed to assess 
the effect on distant disease free survival and CSS.  
 
Electronic Poster: Clinical track: Urology-non-prostate  
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Purpose or Objective: Radical cystectomy (RC) and pelvic 
lymph-node dissection (PLND) are standard procedures in the 
management of non-metastatic muscle invasive bladder 
cancer (MIBC). Loco-regional recurrence (LRR) is a common 
early event associated with a poor prognosis. The aim of this 
study is to evaluate adjuvant radiotherapy (RT) for 
pathological high-risk MIBC.  
 
Material and Methods: We retrospectively reviewed data 
from patients treated by RC from 3 institutions. Inclusion 
criteria were MIBC, histologically proven urothelial carcinoma 
treated by RC and adjuvant RT. Patients with conservative 
surgery were excluded. LRR free-survival, overall survival 
(OS) and metastasis-free survival (MFS) were evaluated. 
Acute toxicities were recorded according to CTCAE V4.0 
scale. 
 
Results: Between January 2000 and December 2013, 57 
patients with a median age of 66 years (45-84) were 
included. Post-operative pathological staging was pT2, pT3 
and pT4 in 16%, 44%, and 39%, respectively. PLND revealed 
28% of pN0, 26% of pN1 and 42% of pN2. For 2 patients, no 
PLND was performed. Median number of lymph-nodes 
retrieved was 10 (2-33). Forty-eight patients (84%) received 
platin-based chemotherapy, 7 in neo-adjuvant and 41 in 
adjuvant setting. For RT, clinical target volume 1 (CTV 1) 
encompasses pelvic lymph nodes for all patients. CTV 1 also 
included cystectomy bed for 37 patients (65%). Median dose 
for CTV 1 was 45 Gy (4-50). Dose complement of 16 Gy (5-22) 
corresponding to CTV 2 was achieved in 53 of cases, 
depending on pathological features. Intensity Modulated RT 
was performed in one third of patients. With a median 
follow-up of 40.4 months, LRR occurred in 8 patients (14%) 
that appeared concomitantly with metastasis in two-third of 
cases. Three-year loco-regional free survival, MFS and OS 
were 45% (IC 95% 0.30-0.60), 39% (IC 95%, 0.25-0.52) and 49% 
(IC 95%, 0.33-0.63), respectively. Acute grade ≥3 toxicities 
were observed in 5 patients (9%). One patient died with 
intestinal fistula in septic context. No survival or toxicity 
predictive factor was identified. 
 
Conclusion: Adjuvant radiotherapy for pathological high-risk 
MIBC is safe and may have oncological benefits. Thus, new 
prospective trials evaluating this approach with modern RT 
techniques should be undertaken. 
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Purpose or Objective: To analyze patients treated for 
recurrent urothelial cancer with radiation therapy with or 
without concomitant chemotherapy after surgical 
intervention that was treated from 2000 to 2012 at our 
centre. 
 
Material and Methods: Our inclusion strategy was to first 
identify patients treated for the relevant ICD-10 codes. A 
number of 270 patients matched the ICD-10 criteria (see 
CONSORT diagram). In a second step, patients that were 
treated at other sites than the pelvis, treated for distant 
metastasis, patients suffering from renal cell cancer and 
cancer of the renal pelvis were excluded. In a third step 
patients treated with radiation doses that are typical for 
palliation (<45Gy) were excluded from the analysis. After 
this, a number of 57 patients remained at the database for 
further analyses. All patients were treated for recurrent 
urothelial cancer of the bladder, of the ureter or of the 
urethra. All patients were treated using 3D conformal 
radiation therapy. Mean prescribed dose was 54.22Gy (range 
45-72Gy). Mean time from first diagnosis to 
radio(chemo)therapy was 22.9 months (range one week to 
276 months). In 24 cases (42.1 %) a concomitant 
chemoradiotherapy was applied. 
 
Results: Mean survival from the beginning of radiation 
treatment was 39.2 months (CI 95 % 24.7 – 53.69 months; 
median survival 14 months CI 95% 6.8 -21.1). Tumor stage at 
the time of surgical intervention did not show an impact on 
overall survival (p=0.96). Patients were divided into three 
subgroups, depending on the surgical intervention prior to 
radiation therapy: most patients were treated by TUR(n=38) 
before the indication to radiation therapy was made, 13 
patients had a TUR followed by cystectomy in their further 
history and in 6 patients early cystectomy was the first type 
